Skip to main content

Table 1 Baseline characteristics of subjects

From: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials

  Overall eGFR (mL/min/1.73 m2)
90 60 to <90 30 to <60 P value
Number of subjects 852 99 525 228  
Age (years) 68.6 ± 8.1 63.7 ± 7.4 68.0 ± 7.7 72.1 ± 7.7 <0.0001*
Sex (male/female) 32/820 5/94 21/504 6/222 0.5110**
Daily/Weekly 604/248 63/36 350/175 191/37 <0.0001**
BMI (kg/m2) 22.2 ± 3.1 21.3 ± 2.8 22.0 ± 2.9 22.9 ± 3.3 <0.0001*
Lumbar spine BMD (g/cm2) 0.67 ± 0.09 0.67 ± 0.08 0.67 ± 0.09 0.67 ± 0.08 0.7043*
  1. Values are mean ± SD
  2. *F test, **Chi square test